Pushing the Boundary of ADC Payload Innovation: Advancing Differentiated Bioconjugate Therapeutics with DUPAC Platform
10:00 am - Monday 12th October 2026
- Enabling Duality 3.0 innovation strategy to advance next-generation ADCs and foster the future of global innovation and collaboration
- Introducing proprietary DUP5, DUP9 and DUP10 payloads designed with distinct mechanisms to overcome Dxd resistance and expand therapeutic reach in hard-to-treat tumor settings
- DB-1326 case study: Exploring TA-MUC1 dual payload ADC, a DUPAC-derived global asset under IND-enabling development
